Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran in Patients with Hereditary Angioedema
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran for the Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Red Metals Corp Invites Shareholders and Investment Community to Visit Them at Booth 2538 at PDAC 2026 in Toronto, March 1-4
Silver Hammer Closes CDN$3,913,617 Non-Brokered Private Placement Pursuant to Listed Issuer Exemption
Sirios Resources Steps Into the Spotlight at Red Cloud Pre-PDAC with James Bay Gold Expansion Strategy
